Clinical Trial · NCT02104310

A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas

Overview

For most brain tumors, radiation treatment is guided by a Magnetic Resonance Imaging (MRI) scan. In this study, information from a special scan, called a Positron Emission Tomography/ Computed Tomography (PET/CT) scan using an amino acid called Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) will also be used. This type of scan has shown promise in being able to better distinguish tumor from normal brain tissue and may help to more accurately plan radiation treatment. This type of scan can also assist the radiation oncologist in identifying the most aggressive regions of the tumor. The goal of this study is to compare the 18F-DOPA PET/CT scan with the MRI scan for identifying where the disease is that needs to be treated with radiation.

Sponsor

Mayo Clinic

Contacts

Nadia N Laack, MD (PRINCIPAL_INVESTIGATOR)

Debra Brinkmann, PhD (PRINCIPAL_INVESTIGATOR)

Deanna Pafundi, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02104310

Drug / Compound

DOPA

Isotope(s):

Target(s):

Amino Acid Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

CT simulation, 18F-DOPA PET imaging, and standard of care pre-radiotherapy MRI scans to be performed at Mayo Clinic Rochester.

Exclusion

Patients previously treated with radiation therapy.